Education, Science, Technology, Innovation and Life
Open Access
Sign In

Analysis and Prospect of Targeted Therapy for Head and Neck Tumors

Download as PDF

DOI: 10.23977/tranc.2018.11001 | Downloads: 15 | Views: 2837

Author(s)

Huang Yizhou 1

Affiliation(s)

1 Bengbu Medical College, Bengbu 233003, China

Corresponding Author

Huang Yizhou

ABSTRACT

Head and neck tumors account for 30% of malignant tumors in the body, which is a key topic in the world. The comparative data of radiotherapy, surgical therapy or chemotherapy for the treatment of these diseases are given. The treatment of epidermal growth factor receptor inhibitor, cyclin dependent kinase inhibitor and insulin-like growth factor receptor inhibitor were analyzed. It is pointed out that molecular targeted therapy is a targeted blocker to interfere with the signal transduction pathway, which is regulated by the specific molecule and is closely related to the occurrence of tumor, so as to inhibit tumor growth and metastasis.

KEYWORDS

Head and neck tumor, targeted therapy, inhibitor review

CITE THIS PAPER

Yizhou, H., Analysis and Prospect of Targeted Therapy for Head and Neck Tumors. Transactions on Cancer (2018) 1: 1-5.

REFERENCES

[1] Corey J. Langer MD.Targeted therapy in head and neck cancer †[J]. Tumor Biology, 2012, 33(3):707.
[2] Ma Yan,Sun Lei,Yu Lei,et al.Advances in targeted treatment of head and neck neoplasms [J].Chinese Journal of Cancer Biotherapy,2014, 21(3):342-347.
[3] Singer S, Arraras J I, Baumann I, et al. Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy — Update of the EORTC QLQ‐H&N35, Phase I[J]. Head & Neck, 2013, 35(9):1 331.
[4] Sacco A G, Worden F P. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors:[J]. Onco Targets Ther, 2016, 9:1 927-1 943.
[5] Gao Yang. Progress in Molecular targeted Therapy of head and neck malignant tumors [J]. Comprehensive clinical practice in China, 2010, 26(5):549-551.
[6] Du Y, Peyser N D, Grandis J R. Integration of molecular targeted therapy with radiation in head and neck cancer.[J]. Pharmacology & Therapeutics, 2014, 142(1):88-98.
[7] Chang J W, Kim C H. Molecular Targeted Therapy of Head and Neck Cancer: Promising Molecular Targets of Post-Epidermal Growth Factor Receptor Era[J]. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2014, 57(9):575.
[8] ShangDandan,Chen Peng. Advances in targeted treatment of head and neck squamous cell carcinoma [J].Chinese Journal of Geriatrics Stomatology,2016, 14(2):120-124.
[9] Seiwert TY,Salama JK,Vokes EE.The chemoradiation paradigm in head and neck cancer[J].Nat Clin Pract Oncol,2007,4(3):156-171
[10] Argiris A,Li Y,Forastiere A.Prognostic factors and long term survivorship in patients with recurrent or metastatic carcinoma of the head and neck,an analysis of 2 Eastern Cooperative Oncology Group randomized trials[J].Cancer,2004,101(10):2 222-2 229 
[11] Leon X,Hitt R,Constenla M,et al.A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy [J].Clin Oncol (R Coll Radiol),2005,17(6):418-424
[12] Moreira J, Tobias A, O'Brien M P, et al. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.[J]. Drugs, 2017, 77(8):1-15.
[13] Kerk S, Finkel K, Pearson A T, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016.
[14] Zhang Xu. Treatment of head and neck neoplasms [J]. medicine 2016(11):00157-00158.
[15] Fukuda S, Hatakeyama H. Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma[J]. Practica oto-rhino-laryngologica, 2012, 105(3):183-191.
[16] Byers L A, Diao L, Ng P K S, et al. Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy.[J]. Journal of Clinical Oncology, 2014.
[17] Jiang Huiyuan, Jiang Bin, Liu Feng, et al. Expression and clinical significance of PD-L1 in head and neck tumors [J]. Journal of Clinical Oncology, 2017, 22(2):124-127.
[18] Wang L X, Agulnik M. Promising new molecular targeted therapies in head and neck cancer.[J]. Drugs, 2013, 73(4):315-325.
[19] Marcu L G, Marcu D. The effect of targeted therapy on recruited cancer stem cells in a head and neck carcinoma model[J]. Cell Proliferation, 2017,19(23):1 789.
[20] Christy A W, Bojan A. Targeted therapy: A novel approach in head and neck cancer.[J]. Indian Journal of Dental Research,2013, 24(2):261.
[21] Guo Wei. Advances in targeted treatment of advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of Oral and Maxillofacial surgery, 2012, 22(2):77-81.
[22] Xiaojing J. Research of targeted therapy in head and neck cancer[J]. Chinese Journal of Cancer Biotherapy, 2014, 21(3):342-347.
[23] Worsham M J, Ali H, Dragovic J, et al. Molecular characterization of head and neck cancer: how close to personalized targeted therapy?[J]. Molecular Diagnosis & Therapy, 2012, 16(4):209-210.
[24] Miao Xiangwan, Xie Minqiang. Advances in molecular targeted therapy of head and neck tumors [J]. Chinese Journal of Otolaryngology and skull Base surgery, 2017, 23(3):290-294.
[25] Koutcher L,Sherman E,Fury M,et al.Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head and neck cancer [J].Int J Radiat Oncol Biol Phys,2011,81(4):915-922
[26] Meng H,Jin Y,Liu H,et al. SNS032 inhibits mTORC1/mTORC2 acti-vity in acute myeloid leukemia cells and has syner gistic activity with perifosine against Akt [J] . J Hematol Oncol, 2013,6: 1 831.
[27] Gojo I,Perl A,Luger S,et al. Phase Ⅰ study of UCN01 and perifosine in patients with relapsed and refractory acute leukemias and highrisk myelodysplastic syndrome [J] . Invest New Drugs, 2013,31( 5) : 1 217-1 227.
[27] Haisa M,The type 1 insulin- like growth factor receptor signalling system and targetedtyrosine kinase inhibition in cancer[J]. J Int Med Res,2013,41(2): 253-264.
[29] Shin DH,Min HY,El- Naggar AK, et al. Akt/mTOR counteract the antitumor activities of cixutumumab,an anti- insulin- like growth factor I receptor monoclonal an tibody[J]. Mol Cancer Ther,2011,10(12): 2 437- 2 448.
[30] Limesand KH,Chibly AM,Fribley A. Impact of targeting insulin- like growth factor signaling in head and neck cancers[J]. Growth Horm IGF Res,2013,23(5): 135-140.
[31] Jameson MJ,Beckler AD,Taniguchi LE,et al. Activation of the insulin- like growth factor- 1 receptor induces resistance to epidermal growth factor receptor antago- nism in head and neck squamous carcinoma cells [J]. Mol Cancer Ther,2011,10(11): 2 124-2 134.
[32] Rieke DT, Klinghammer K, Keilholz U. Targeted Therapy of Head and Neck Cancer.[J]. Oncology research and treatment, 2016, 39(12):7803
[33] Sun Lili, Bai Yuxian. Advances in targeted treatment of head and neck squamous cell carcinoma [J]. Chinese Journal of clinicians: electronic Edition,2013, 7(22):10271-10274.
[34] Nakashima T. Molecular targeted therapy for head and neck cancer[J]. Nippon Koku Geka Gakkai Zasshi, 2014, 60(7):404-406.
[35] Strieth S, Ernst B P. [Recent Developments Towards Molecularly Targeted Therapy of Head and Neck Cancer].[J]. Laryngo- rhino- otologie, 2017,22(21):280-283.
[36] Zhou Lian, Luo Wenlong. Advances in targeted treatment of laryngeal malignant tumors [J]. Journal of Applied Medicine, 2014(13):2168-2171.
[37] Du Lifa, Wang Junjie. Basic study of epidermal growth factor receptor targeted therapy for head and neck squamous cell carcinoma [J]. Cancer Progress,2012, 10(4):355-359.
[38] Xu Haixia, Peng Shi Dong. Research progress of BRMS1 gene in head and neck cancer [J]. Inner Mongolia Journal of medicine, 2015, 47(9):1 063-1 066.
[39] Shao Xiaolin, Zhang Tao. Advances in the study of long chain non-coding RNA associated with head and neck neoplasms [J]. Journal of Applied Oncology, 2016, 30(1):88-92.
[40] Byeon H K. Crosstalk Mechanisms Following Targeted Therapy in Head and Neck Cancer[J].  2016, 59(3):181.

Downloads: 40
Visits: 4833

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.